Covidien (UNKNOWN:COV.DL) and Medtronic (NYSE:MDT) announced a tie-up over the weekend for $42.9 billion, and Covidien promptly shot up over 20% today on investor optimism around the deal. And with Medtronic offering a 29% premium to last Friday's close and both boards of directors behind the proposal, there appears to be much reason for optimism about the deal going through.

But we're long-term investors, so the big question for us is also the simplest: Does this acquisition make sense?

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson give their answer.